Cargando…

SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS

Although reduced intensity (RIC) and nonmyeloablative (NMA) conditioning regimens have been used for over a decade, their relative efficacy versus myeloablative (MA) approaches to allogeneic hematopoietic cell transplantation (HCT) in patients with acute myelogenous leukemia (AML) and myelodysplasia...

Descripción completa

Detalles Bibliográficos
Autores principales: Luger, Selina M., Ringdén, Olle, Zhang, Mei-Jie, Pérez, Waleska S., Bishop, Michael R., Bornhauser, Martin, Bredeson, Christopher N., Cairo, Mitchell S., Copelan, Edward A., Gale, Robert Peter, Giralt, Sergio A., Gulbas, Zafer, Gupta, Vikas, Hale, Gregory A., Lazarus, Hillard M., Lewis, Victor Anthony, Lill, Michael C., McCarthy, Philip L., Weisdorf, Daniel J., Pulsipher, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134582/
https://www.ncbi.nlm.nih.gov/pubmed/21441963
http://dx.doi.org/10.1038/bmt.2011.69
_version_ 1782207998037327872
author Luger, Selina M.
Ringdén, Olle
Zhang, Mei-Jie
Pérez, Waleska S.
Bishop, Michael R.
Bornhauser, Martin
Bredeson, Christopher N.
Cairo, Mitchell S.
Copelan, Edward A.
Gale, Robert Peter
Giralt, Sergio A.
Gulbas, Zafer
Gupta, Vikas
Hale, Gregory A.
Lazarus, Hillard M.
Lewis, Victor Anthony
Lill, Michael C.
McCarthy, Philip L.
Weisdorf, Daniel J.
Pulsipher, Michael A.
author_facet Luger, Selina M.
Ringdén, Olle
Zhang, Mei-Jie
Pérez, Waleska S.
Bishop, Michael R.
Bornhauser, Martin
Bredeson, Christopher N.
Cairo, Mitchell S.
Copelan, Edward A.
Gale, Robert Peter
Giralt, Sergio A.
Gulbas, Zafer
Gupta, Vikas
Hale, Gregory A.
Lazarus, Hillard M.
Lewis, Victor Anthony
Lill, Michael C.
McCarthy, Philip L.
Weisdorf, Daniel J.
Pulsipher, Michael A.
author_sort Luger, Selina M.
collection PubMed
description Although reduced intensity (RIC) and nonmyeloablative (NMA) conditioning regimens have been used for over a decade, their relative efficacy versus myeloablative (MA) approaches to allogeneic hematopoietic cell transplantation (HCT) in patients with acute myelogenous leukemia (AML) and myelodysplasia (MDS) is unknown. We compared disease status, donor, graft and recipient characteristics with outcomes of 3731 MA with 1448 RIC/NMA procedures performed at 217 centers between 1997 and 2004. Five year univariate probabilities and multivariate relative risk (RR) outcomes of relapse, transplant related mortality (TRM), disease free survival (DFS) and overall survival (OS) are reported. Adjusted OS at 5 years was 34%, 33%, and 26% for MA, RIC and NMA transplants, respectively. NMA conditioning resulted in inferior DFS and OS but there was no difference in DFS and OS between RIC and MA regimens. Late TRM negates early decreases in toxicity with RIC and NMA regimens. Our data suggest higher regimen intensity may contribute to optimal survival in patients with AML/MDS, suggesting roles for both regimen intensity and graft vs. leukemia in these diseases. Prospective studies comparing regimens are needed to confirm this finding and determine the optimal approach to patients who are eligible for either MA or RIC/NMA conditioning.
format Online
Article
Text
id pubmed-3134582
institution National Center for Biotechnology Information
language English
publishDate 2011
record_format MEDLINE/PubMed
spelling pubmed-31345822012-08-01 SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS Luger, Selina M. Ringdén, Olle Zhang, Mei-Jie Pérez, Waleska S. Bishop, Michael R. Bornhauser, Martin Bredeson, Christopher N. Cairo, Mitchell S. Copelan, Edward A. Gale, Robert Peter Giralt, Sergio A. Gulbas, Zafer Gupta, Vikas Hale, Gregory A. Lazarus, Hillard M. Lewis, Victor Anthony Lill, Michael C. McCarthy, Philip L. Weisdorf, Daniel J. Pulsipher, Michael A. Bone Marrow Transplant Article Although reduced intensity (RIC) and nonmyeloablative (NMA) conditioning regimens have been used for over a decade, their relative efficacy versus myeloablative (MA) approaches to allogeneic hematopoietic cell transplantation (HCT) in patients with acute myelogenous leukemia (AML) and myelodysplasia (MDS) is unknown. We compared disease status, donor, graft and recipient characteristics with outcomes of 3731 MA with 1448 RIC/NMA procedures performed at 217 centers between 1997 and 2004. Five year univariate probabilities and multivariate relative risk (RR) outcomes of relapse, transplant related mortality (TRM), disease free survival (DFS) and overall survival (OS) are reported. Adjusted OS at 5 years was 34%, 33%, and 26% for MA, RIC and NMA transplants, respectively. NMA conditioning resulted in inferior DFS and OS but there was no difference in DFS and OS between RIC and MA regimens. Late TRM negates early decreases in toxicity with RIC and NMA regimens. Our data suggest higher regimen intensity may contribute to optimal survival in patients with AML/MDS, suggesting roles for both regimen intensity and graft vs. leukemia in these diseases. Prospective studies comparing regimens are needed to confirm this finding and determine the optimal approach to patients who are eligible for either MA or RIC/NMA conditioning. 2011-03-28 2012-02 /pmc/articles/PMC3134582/ /pubmed/21441963 http://dx.doi.org/10.1038/bmt.2011.69 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Luger, Selina M.
Ringdén, Olle
Zhang, Mei-Jie
Pérez, Waleska S.
Bishop, Michael R.
Bornhauser, Martin
Bredeson, Christopher N.
Cairo, Mitchell S.
Copelan, Edward A.
Gale, Robert Peter
Giralt, Sergio A.
Gulbas, Zafer
Gupta, Vikas
Hale, Gregory A.
Lazarus, Hillard M.
Lewis, Victor Anthony
Lill, Michael C.
McCarthy, Philip L.
Weisdorf, Daniel J.
Pulsipher, Michael A.
SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
title SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
title_full SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
title_fullStr SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
title_full_unstemmed SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
title_short SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
title_sort similar outcomes using myeloablative versus reduced intensity allogeneic transplant preparative regimens for aml or mds
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134582/
https://www.ncbi.nlm.nih.gov/pubmed/21441963
http://dx.doi.org/10.1038/bmt.2011.69
work_keys_str_mv AT lugerselinam similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT ringdenolle similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT zhangmeijie similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT perezwaleskas similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT bishopmichaelr similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT bornhausermartin similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT bredesonchristophern similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT cairomitchells similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT copelanedwarda similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT galerobertpeter similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT giraltsergioa similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT gulbaszafer similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT guptavikas similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT halegregorya similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT lazarushillardm similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT lewisvictoranthony similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT lillmichaelc similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT mccarthyphilipl similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT weisdorfdanielj similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds
AT pulsiphermichaela similaroutcomesusingmyeloablativeversusreducedintensityallogeneictransplantpreparativeregimensforamlormds